Characterization of Bile Acid Pathway in Obesity
Status: | Recruiting |
---|---|
Conditions: | Obesity Weight Loss |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 6/13/2018 |
Start Date: | January 2017 |
End Date: | January 2020 |
Contact: | Judith Davis |
Email: | davis.judith@mayo.edu |
Phone: | 507-538-5861 |
It is unknown whether the bile acid pathway is altered in obesity. This study is designed to
compare obesity and health to determine if the bile acid pathway differs depending on health
state.
compare obesity and health to determine if the bile acid pathway differs depending on health
state.
This is a single center study involving diet intervention, including healthy obese and
healthy normal weight participants. Participants will maintain their normal diet for 1 week,
eat a high fat and high calorie diet for 1 week, return to their normal diet for 1 week, and
eat a low fat and low calorie diet for 1 week, to study the effect of diet on the bile acid
pathway in normal weight and obesity. During their first normal diet week, the high calorie
week, and the low calorie week, blood samples will be collected at defined times to measure
cholesterol, glycemia, Fibroblast Growth Factor 19 (FGF-19), Bile Acid (BA), C4, and
incretins (GLP-1 (glucagon-like peptide-1), peptide tyrosine tyrosine (PYY 3-36)) fasting
levels and responses to the meal. Stool samples will be collected for 48 hour BA excretion.
healthy normal weight participants. Participants will maintain their normal diet for 1 week,
eat a high fat and high calorie diet for 1 week, return to their normal diet for 1 week, and
eat a low fat and low calorie diet for 1 week, to study the effect of diet on the bile acid
pathway in normal weight and obesity. During their first normal diet week, the high calorie
week, and the low calorie week, blood samples will be collected at defined times to measure
cholesterol, glycemia, Fibroblast Growth Factor 19 (FGF-19), Bile Acid (BA), C4, and
incretins (GLP-1 (glucagon-like peptide-1), peptide tyrosine tyrosine (PYY 3-36)) fasting
levels and responses to the meal. Stool samples will be collected for 48 hour BA excretion.
Normal Weight Inclusion Criteria:
- Women of childbearing potential will have negative pregnancy tests within 48 hours of
enrollment
- BMI: 18.5-25 kg/m2
Obese Inclusion Criteria:
- Women of childbearing potential will have negative pregnancy tests within 48 hours of
enrollment
- BMI: ≥ 30 kg/m2
Exclusion Criteria for both Normal Weight and Obese Participants:
- History of abdominal surgery including cholecystectomy and other than appendectomy,
Caesarian section or tubal ligation.
- Positive history of chronic gastrointestinal diseases, or systemic disease that could
affect gastrointestinal motility, or use of medications that may alter
gastrointestinal motility, appetite or absorption, e.g., orlistat, phentermine.
- Significant untreated psychiatric dysfunction based upon screening with the Hospital
Anxiety and Depression Inventory (HAD), a self-administered alcoholism screening test
(AUDIT-C) and the Questionnaire on Eating and Weight Patterns (binge eating disorders
and bulimia). If such a dysfunction is identified by a HAD score >11 or difficulties
with substance or eating disorders, the participant will be excluded and given a
referral letter to his/her primary care doctor for further appraisal and follow-up.
The AUDIT-C is a 3-item alcohol screening questionnaire that reliably identifies
participants who are hazardous alcohol drinkers or have active alcohol use disorders.
In men, a score of 4 or more is above the recommended limits will be reviewed by study
personnel. In women, a score of 3 or more is above the recommended limits will be
reviewed by study personnel. However when the points are above recommended limits, the
provider will review the patient's alcohol intake over the past few months to confirm
accuracy and determine study eligibility..
- Intake of medication, whether prescribed or over the counter (except multivitamins),
within 7 days of the study. Exceptions are birth control pill, estrogen replacement
therapy, and thyroxin replacement therapy.
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Phone: 507-538-5861
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials